PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients

Cancers - Switzerland
doi 10.3390/cancers10090314
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Mutations in KRAS Codon 12 Predict Poor Survival in Chinese Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2017English

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

Frontiers in Oncology
Cancer ResearchOncology
2019English

Hypertension and Overall Survival in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Containing Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2011English

Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Effect and Safety of Bevacizumab-Containing Chemotherapy Treatment in Chinese Patients With Metastatic Colorectal Cancer

OncoTargets and Therapy
OncologyPharmacology
2013English

Reply: Capecitabine and Bevacizumab as First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

PCN22 Safety Profile of Bevacizumab in Metastatic Colorectal Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Bevacizumab May Overcome Clinical Tumor Drug Resistance to Irinotecan Based Chemotherapy in Patients With Metastatic Colorectal Cancer: Case Report

The Open Colorectal Cancer Journal
2010English

Biomarker Signatures Correlate With Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy